Evidence map›Paper›PMID 36560832›Full record

ArticleViruses2022

Insights from the Infection Cycle of VSV-ΔG-Spike Virus.

Elad Milrot, Shlomi Lazar, Ofir Schuster, Efi Makdasi, Shlomo Shmaya, Yfat Yahalom-Ronen, Hadas Tamir, Orly Laskar

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 54% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Elad MilrotDepartment of Infectious Diseases, Israel Institute of Biological Research (IIBR), Ness-Ziona 74100, Israel.
Shlomi LazarDepartment of Pharmacology, Israel Institute of Biological Research (IIBR), Ness-Ziona 74100, Israel.
Ofir SchusterDepartment of Infectious Diseases, Israel Institute of Biological Research (IIBR), Ness-Ziona 74100, Israel.ORCID 0000-0001-6379-9292
Efi MakdasiDepartment of Infectious Diseases, Israel Institute of Biological Research (IIBR), Ness-Ziona 74100, Israel.
Shlomo ShmayaDepartment of Infectious Diseases, Israel Institute of Biological Research (IIBR), Ness-Ziona 74100, Israel.
Yfat Yahalom-RonenDepartment of Infectious Diseases, Israel Institute of Biological Research (IIBR), Ness-Ziona 74100, Israel.
Hadas TamirDepartment of Infectious Diseases, Israel Institute of Biological Research (IIBR), Ness-Ziona 74100, Israel.
Orly LaskarDepartment of Infectious Diseases, Israel Institute of Biological Research (IIBR), Ness-Ziona 74100, Israel.ORCID 0000-0003-3109-6554
Israel Institute for Biological Research · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fundamental key processes in viral infection cycles generally occur in distinct cellular sites where both viral and host factors accumulate and interact. These sites are usually termed viral replication organelles, or viral factories (VF). The generation of VF is accompanied by the synthesis of viral proteins and genomes and involves the reorganization of cellular structure. Recently, rVSV-ΔG-spike (VSV-S), a recombinant VSV expressing the SARS-CoV-2 spike protein, was developed as a vaccine candidate against SARS-CoV-2. By combining transmission electron microscopy (TEM) tomography studies and immuno-labeling techniques, we investigated the infection cycle of VSV-S in Vero E6 cells. RT-real-time-PCR results show that viral RNA synthesis occurs 3-4 h post infection (PI), and accumulates as the infection proceeds. By 10-24 h PI, TEM electron tomography results show that VSV-S generates VF in multi-lamellar bodies located in the cytoplasm. The VF consists of virus particles with various morphologies. We demonstrate that VSV-S infection is associated with accumulation of cytoplasmatic viral proteins co-localized with dsRNA (marker for RNA replication) but not with ER membranes. Newly formed virus particles released from the multi-lamellar bodies containing VF, concentrate in a vacuole membrane, and the infection ends with the budding of particles after the fusion of the vacuole membrane with the plasma membrane. In summary, the current study describes detailed 3D imaging of key processes during the VSV-S infection cycle.

Indexed as

COVID-19Vesicular stomatitis Indiana virusHumansSARS-CoV-2Spike Glycoprotein, CoronavirusViral ProteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2Viral Proteinselectron tomographyRNA virusspike proteintransmission electron microscopyvesicular stomatitis virusviral factories

Identifiers

PMID36560832
PMCPMC9788095
OpenAlexW4311951863

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.